T2 Biosystems to Host Symposium at 27th European Congress of Clinical Microbiology and Infectious Diseases
April 19 2017 - 09:04AM
T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that the company
will be hosting a special symposium highlighting the clinical and
economic benefits of testing with the T2Candida® Panel and
previewing the performance of the T2Bacteria™ Panel at the 27th
European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID) in Vienna, Austria on Saturday, April 22. ECCMID is an
annual conference that brings together leading experts to discuss
the latest developments in infectious disease, infection control
and clinical microbiology.
At the symposium, leading experts from several U.S. and European
hospitals will discuss how the FDA-cleared and CE-marked T2Candida
Panel is delivering significant improvements in patient outcomes in
conjunction with substantial economic savings. In addition, early
performance data from T2Bacteria Panel and our sepsis product
pipeline will be shared, highlighting the promise to deliver the
same significant benefits of rapid and highly sensitive
direct-from-blood detection as T2Candida.
Chair: Maurizio Sanguinetti, MD, Policlinico
Universitario Agostino Gemelli, Rome, Italy
Presentations: Proven Clinical Benefit
and Economic Savings of T2Candida in Hospital Practice
Sandy J. Estrada, Pharm.D., BCPS, Lee Health System, Florida,
USA
T2Candida – Impactful Case Study Reviews
Patricia Muñoz, MD, PhD, Hospital General Universitario Gregorio
Marañón, Madrid, Spain
Early Experience with T2Bacteria - Direct-from-Blood
Species Identification Giulia De Angelis, MD, Policlinico
Universitario Agostino Gemelli, Rome, Italy
The Future of Rapid, Direct-from-Blood Sepsis
Diagnostics Rahul Dhanda, T2 Biosystems, Massachusetts,
USA
Date/Time/Location Saturday 22 April 2017 13:30
- 15:30pm Reed Messe Wien GmbH (HALL C)
Messeplatz 1, Postfach 277 A-1021 Wien
Be sure to follow all T2 specific developments and news from the
#ECCMID2017 conference on Twitter via the T2 Biosystems handle
@T2Bio.
Media interested in one-on-one interviews live or by phone
before or after the T2 symposium should contact the T2 press
coordinators below to set up an interview.
Click here for highlights of IDWeek 2016 hospital data detailing
improvements in patient care and hospital savings from
T2Candida.
In addition, T2 Biosystems will be presenting a poster on the
T2Lyme Panel:
P0342. “Direct detection of early-stage Lyme
borreliosis using T2 magnetic resonance”Session: Challenges in
diagnostic bacteriologyPresenter: T2 BiosystemsDate: Saturday, 22
April 2017
About T2 BiosystemsT2 Biosystems is focused on
developing innovative diagnostic products to improve patient
health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel
targeting sepsis and a range of additional products in development,
T2 Biosystems is an emerging leader in the field of in vitro
diagnostics. The Company is utilizing its proprietary T2 Magnetic
Resonance platform, or T2MR®, to develop a broad set of
applications aimed at lowering mortality rates, improving patient
outcomes and reducing the cost of healthcare by helping medical
professionals make targeted treatment decisions earlier. T2MR
enables the fast and sensitive detection of pathogens, biomarkers
and other abnormalities in a variety of unpurified patient sample
types, including whole blood, eliminating the time-consuming sample
prep required in current methods. For more information, please
visit www.t2biosystems.com.
Media Contacts:
Amy Crosby, T2 Biosystems
acrosby@t2biosystems.com
+1 (978) 478-8451
On-site contact
Matthew McKillip, T2 Biosystems
mmckillip@t2biosystems.com
+1 (518) 577-3466
Investor Contact:
Tucker Elcock, Teneo Strategy
Tucker.Elcock@teneostrategy.com
+1 (212) 886-9319
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Feb 2024 to Mar 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2023 to Mar 2024